ESSA Pharma Inc.:
Sm molecule drugs: castration-resistant prostate cancer. EPI-506, exp to enter clinic YE19 (second-gen compound). Developing compounds binding to N-terminus of AR and block signaling. MOA potentially overcomes resistance mechanisms currently seen in metastatic prostate cancer.
999 West Broadway Street Suite 720
Vancouver, British Columbia
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by